



## Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

May 3, 2023

SAN CARLOS, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023, at 5:20 p.m. ET / 2:20 p.m. PT.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company's website at <http://investors.vaxcyte.com>. A replay of the webcast will be available for approximately 30 days following the conference.

### About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte's lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit [www.vaxcyte.com](http://www.vaxcyte.com).

### Contacts:

Jennifer Zibuda, Senior Director, Investor Relations  
Vaxcyte, Inc.  
860-729-8902  
[investors@vaxcyte.com](mailto:investors@vaxcyte.com)

Janet Graesser, Vice President, Corporate Communications and Investor Relations  
Vaxcyte, Inc.  
917-685-8799  
[media@vaxcyte.com](mailto:media@vaxcyte.com)